Search Results
Advertisement
Your search for Parminder Singh, MD,Parminder Singh, MD matches 2 pages
Showing 1 - 2Enfortumab Vedotin Plus Pembrolizumab Yields Benefit in Key Subgroups With Advanced Urothelial Cancer
The combination of the nectin-4–directed antibody-drug conjugate enfortumab vedotin-ejfv plus the PD-1 inhibitor pembrolizumab achieved favorable rates of progression-free survival, overall survival, and objective responses compared with chemotherapy among key subgroups of patients with previously...
SWOG Launches First Prospective Registration Trial With Atezolizumab in BCG-Unresponsive Non–Muscle Invasive Bladder Cancer
The standard of care for patients with bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non–muscle invasive bladder cancer is radical cystectomy. Novel therapies that allow patients to preserve their bladder are urgently needed. SWOG (formerly the Southwest Oncology Group), a member of...
Advertisement
Advertisement
Nov
Today In Oncology21
Advertisement
© 2024 HSP News Service, L.L.C.
